Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer

This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with prostate cancer that has not spread to other parts of the body (localized). ART is a type of radiation therapy that uses information gathered during the treatment cycle to inform, guide, and alter future radiation treatments with respect to location and dose. It may be able to deliver radiation to the site of disease over a shorter time and with smaller margi

Trial Details

NCT ID
NCT06325046
Phase
NA
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Computed Tomography
  • Cone-Beam Computed Tomography
  • Image-Guided Adaptive Radiation Therapy
  • Magnetic Resonance Imaging
  • Stereotactic Ablative Radiotherapy
  • Survey Administration
Locations (sample)
  • Albert Lea, Minnesota, United States|43.64801,-93.36827
  • Mankato, Minnesota, United States|44.15906,-94.00915
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Eau Claire, Wisconsin, United States|44.81135,-91.49849
  • La Crosse, Wisconsin, United States|43.80136,-91.23958

Key Eligibility Criteria

  • Gender assigned male at birth: age ≥ 18 years
  • Histological confirmation of prostate adenocarcinoma
  • National Comprehensive Cancer Network (NCCN) (Prostate Cancer version 4.2022) low- to intermediate-risk prostate adenocarcinoma
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →